No valuation for Ambagon Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($108.0M) and the funding record below are the closest available signals.
- ·The complete investor list: 13 names
- ·Watch Ambagon Therapeutics: the Monday email on marks, rounds and moves
Ambagon Therapeutics funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jan 2025 | Early Stage VC | $5.0M | ▮ | ▮ |
| Jan 2022 | Early Stage VC (Series A) | $85.0M | ▮ | ▮ |
| Jul 2020 | Early Stage VC | $5.4M | ▮ | ▮ |
Membership and data by Private Market View
How much has Ambagon Therapeutics raised?
Ambagon Therapeutics has raised $108 million across 3 recorded rounds since 2020. The largest was an $85 million Series A in Jan 2022; the most recent was a $5 million early-stage round in Jan 2025.
Ambagon Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently in Feb 2025 ($5 million sold to 4 investors).
How Ambagon Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Ambagon Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked about Ambagon Therapeutics
- How much has Ambagon Therapeutics raised?
- Ambagon Therapeutics has raised $108.0M in total funding across 3 recorded rounds.
- When did Ambagon Therapeutics last raise?
- Ambagon Therapeutics last raised in Jan 2025 (Early Stage VC), raising $5.0M.